癌代謝を標的とする:脂肪酸合成酵素 (FASN) 阻害剤の治療的可能性
PubMedで要約を見る
まとめ
この要約は機械生成です。脂肪酸合成酵素 (FASN) は癌の成長に不可欠です. FASNを阻害すると,がんの代謝が妨げられ,特に他の治療法と併用すると,有望な治療法となる.
科学分野
- 生物化学
- 腫瘍学
- 代謝経路
背景
- メタボリックリワイヤリングは 癌の重要な特徴です
- 脂肪酸合成酵素 (FASN) は多くの癌で上位調節され,予後が悪いと相関しています.
- FASNは腫瘍細胞の増殖と生存に不可欠なデノボリポゲネシスを誘発する.
研究 の 目的
- 癌代謝におけるFASNの役割を検討する.
- FASN阻害剤の治療の可能性を評価する.
- 癌におけるFASNの構造,機能,および調節について議論する.
主な方法
- 癌におけるFASNの役割に関する文献レビュー.
- 様々な癌 (肺,結腸,脳,乳腺,前立腺) のFASN過剰発現の分析
- デニファンスタット (TVB- 2640) を含むFASN阻害剤に関する臨床前および臨床データの検討.
主要な成果
- FASNの阻害は脂質生物合成を妨害し,がん細胞の代謝ストレスとアポトーシスを誘発する.
- Denifanstatは,臨床前モデルで抗腫瘍活性を示し,早期臨床試験の結果は有望である.
- FASN阻害は腫瘍の成長を阻害し,化学療法と標的薬の有効性を高めます.
結論
- FASNはがん治療の重要なターゲットです.
- デニファンスタットのような選択的なFASN阻害剤は,重要な治療的可能性を秘めています.
- FASN阻害剤を併用した併用療法により,治療結果が改善され,患者の選択のためにバイオマーカーの特定が必要となる.
関連する概念動画
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

